Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some safety statements (mechanism, indications, and general PPI risks) align with the provided label excerpts, but several claims are not supported by the excerpts (generic/patent/price/competition statements and multiple “common side effects” not matching label-listed adverse reactions). Overall, alignment is partial due to significant unsupported/non-label content.
Category Scores
Accurate Statements
Rabeprazole sodium is a proton pump inhibitor (PPI).
12.1 Mechanism of Action: suppresses gastric acid secretion by inhibiting the gastric H+,K+ATPase; characterized as a gastric proton-pump inhibitor.
Rabeprazole sodium works by reducing stomach acid production.
12.1 Mechanism of Action and 12.2 Pharmacodynamics: suppresses gastric acid secretion; decreases intragastric acidity.
There can be differences among PPIs in onset of action.
Supported indirectly by 12.2 Pharmacodynamics describing onset within one hour after a 20 mg dose; no explicit cross-PPI comparison stated in excerpts.
There can be differences among PPIs in duration of effect.
Supported indirectly by 12.2 describing pH>3 time; no explicit cross-PPI comparison stated in excerpts.
There can be differences among PPIs in metabolic pathways.
Not supported in the provided excerpts; see unsupported section.
Patient response to specific PPIs can vary.
Not explicitly stated in provided excerpts; however, the label includes efficacy and trial outcomes variability by study results.
Long-term use of PPIs, including rabeprazole sodium, has been associated with an increased risk of bone fractures.
5.5 Bone Fracture: PPI therapy may be associated with an increased risk for osteoporosis-related fractures.
Long-term use of PPIs, including rabeprazole sodium, has been associated with certain vitamin deficiencies.
5 Warnings and Precautions: Cyanocobalamin (vitamin B-12) Deficiency; implies vitamin deficiency risk (B-12) with long-term acid suppression.
Long-term use of PPIs, including rabeprazole sodium, has been associated with vitamin B12 deficiency.
5 Warnings and Precautions: Cyanocobalamin (vitamin B-12) Deficiency may lead to malabsorption of B-12 with long period acid-suppressing medications.
Long-term use of PPIs, including rabeprazole sodium, has been associated with kidney problems.
5.3 Acute Interstitial Nephritis: discontinue if acute interstitial nephritis develops (renal-related adverse effect).
Rabeprazole sodium is used to treat gastroesophageal reflux disease (GERD).
1 Indications & Usage: healing and symptomatic relief of erosive/ulcerative GERD; maintenance of healing and reduction in relapse of heartburn symptoms; symptomatic GERD indications.
Rabeprazole sodium is used to treat peptic ulcers.
1 Indications & Usage: short-term treatment in healing and symptomatic relief of duodenal ulcers.
Rabeprazole sodium is used to treat Zollinger-Ellison syndrome.
1 Indications & Usage: long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
Unsupported Statements
The original patents for rabeprazole sodium have expired.
Patent expiration is not addressed in the provided FDA label excerpts.
The expiration of rabeprazole sodium patents allows for the development and marketing of generic versions.
Generic development/marketing rationale is not addressed in the provided FDA label excerpts.
Rabeprazole sodium generics are manufactured by numerous pharmaceutical companies.
Manufacturing/number of manufacturers for generics is not addressed in the provided FDA label excerpts.
The availability of generic rabeprazole sodium increases competition.
Market/competition statements are not addressed in the provided FDA label excerpts.
The availability of generic rabeprazole sodium generally leads to lower prices for the medication.
Price statements are not addressed in the provided FDA label excerpts.
There can be differences among PPIs in metabolic pathways.
Metabolic pathway differences among PPIs are not addressed in the provided label excerpts.
Patient response to specific PPIs can vary.
Variability is not explicitly stated as such in the provided label excerpts.
Physicians may select a particular PPI based on individual patient needs and clinical experience.
Prescriber selection guidance is not addressed in the provided FDA label excerpts.
Common side effects of rabeprazole sodium can include headache.
Headache is not listed as an adverse reaction in ≥2% adult clinical studies excerpt (6.1 lists pain, pharyngitis, flatulence, infection, constipation).
Common side effects of rabeprazole sodium can include diarrhea.
Diarrhea is discussed as Clostridium difficile-associated diarrhea in warnings, but “common side effects” list is not supported by the provided 6.1 excerpt.
Common side effects of rabeprazole sodium can include nausea.
Nausea is not listed in the provided ≥2% adverse reactions excerpt.
Common side effects of rabeprazole sodium can include abdominal pain.
Abdominal pain is not listed in the provided ≥2% adverse reactions excerpt (6.1 does list pain, but not specified as abdominal pain).
Common side effects of rabeprazole sodium can include dizziness.
Dizziness is not listed in the provided ≥2% adverse reactions excerpt.
Contradictions
Important Omissions
No administration and timing details were provided to support any implicit dosing/usage safety claims (e.g., swallowing whole; indications differ for food vs after meal).
Importance:
Moderate
No mention that in adults symptomatic response does not preclude gastric malignancy and that additional follow-up/testing may be needed.
Importance:
Moderate
No mention of key contraindications (e.g., PPI contraindication with rilpivirine-containing products) or drug interaction monitoring (e.g., warfarin INR).
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Unsupported “common side effects” statements may mislead expectations; omission of prominent contraindication/interaction and malignancy follow-up guidance increases the likelihood of incomplete label-aligned safety communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided FDA label excerpts (generic/patent/price/competition statements and multiple “common side effects” not matching 6.1 clinical study adverse reactions). Also key safety label items (notably contraindications/interactions) were omitted.
Suggested Improvement
Remove non-label patent/generic/price statements; align adverse reaction wording to label-supported reactions (e.g., those reported ≥2% in studies) and distinguish warning events (e.g., C. difficile) from “common side effects.” If safety messaging is included, incorporate major contraindications (rilpivirine) and prominent precautions/monitoring (e.g., warfarin INR, acute interstitial nephritis).